Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Diffuse Large Cell Lymphoma Relapsed/Refractory

Interventions: Drug: Ofatumumab
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2012-03-15

Last Posted Date: 2022-06-29

Lead Sponsor: C. Babis Andreadis

Target Recruit Count: 19

Registration Number: NCT01555541

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Erythroleukemia (M6a)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Biological: trebananib
Other: laboratory biomarker analysis
Drug: cytarabine
Other: pharmacological study

First Posted Date: 2012-03-15

Last Posted Date: 2022-09-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 24

Registration Number: NCT01555268

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University of Rochester, Rochester, New York, United States

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: PF-04449913
Drug: Low dose ARA-C (LDAC)
Drug: Daunorubicin
Drug: Decitabine
Drug: Cytarabine

First Posted Date: 2012-03-07

Last Posted Date: 2020-03-03

Lead Sponsor: Pfizer

Target Recruit Count: 255

Registration Number: NCT01546038

Locations: 🇺🇸
Keck Hospital of USC, Los Angeles, California, United States
🇺🇸
University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States
🇺🇸
LAC & USC Medical Center, Los Angeles, California, United States

and more 75 locations

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Y Zevalin
Drug: In Zevalin
Drug: Rituxan
Drug: BCNU
Drug: VP -16
Drug: Ara-C
Drug: Melphalan
Procedure: Stem Cell Infusion
Drug: G-CSF

First Posted Date: 2012-02-24

Last Posted Date: 2014-09-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT01538472

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Stage I Mantle Cell Lymphoma
Stage II Contiguous Mantle Cell Lymphoma
Stage II Non-Contiguous Mantle Cell Lymphoma
Stage III Mantle Cell Lymphoma
Stage IV Mantle Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Biological: Ofatumumab
Drug: Vincristine Sulfate

First Posted Date: 2012-02-06

Last Posted Date: 2024-02-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 37

Registration Number: NCT01527149

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Phase 2

Recruiting

Conditions: Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Decitabine

First Posted Date: 2012-01-24

Last Posted Date: 2024-06-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 160

Registration Number: NCT01515527

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: thiotepa
Procedure: stem cell transplant
Drug: G-CSF

First Posted Date: 2012-01-18

Last Posted Date: 2021-08-17

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 113

Registration Number: NCT01511562

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 123 locations

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Phase 2

Terminated

Conditions: Acute Myelogenous Leukemia
Chronic Myelogenous Leukemia
Aplastic Anemia
Acute Lymphocytic Leukemia
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Multiple Myeloma
Hodgkins Disease
Non-Hodgkins Lymphoma

Interventions: Drug: Busulfan
Drug: Clofarabine
Drug: Fludarabine
Drug: Melphalan
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2011-12-28

Last Posted Date: 2013-11-25

Lead Sponsor: Texas Oncology Cancer Center

Target Recruit Count: 1

Registration Number: NCT01500161

Locations: 🇺🇸
Texas Oncology, Amarillo, Texas, United States

Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a

Phase 3

Completed

Conditions: Acute Myeloid Leukaemia

Interventions: Drug: Cytarabine
Biological: human stem cells

First Posted Date: 2011-12-22

Last Posted Date: 2024-01-31

Lead Sponsor: University of Leipzig

Target Recruit Count: 1222

Registration Number: NCT01497002

Locations: 🇩🇪
University of Leipzig, Hematology, Leipzig, Germany

Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients

Phase 2

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Ofatumumab
Drug: Etoposide
Drug: Ifosfamid
Drug: Mesna
Drug: Cytarabine
Drug: Methotrexate
Drug: Leukovorin
Drug: Granulocyte-Colony Stimulating Factor

First Posted Date: 2011-11-29

Last Posted Date: 2021-12-27

Lead Sponsor: Polish Lymphoma Research Group

Target Recruit Count: 77

Registration Number: NCT01481272

Locations: 🇵🇱
Instytut Hematologii i Transfuzjologii, Warszawa, Mazowieckie, Poland
🇵🇱
Dolnośląskie Centrum Transplantacji Komórkowych, Wrocław, Dolnośląskie, Poland
🇵🇱
Uniwersyteckie Cenrum Medyczne, Gdańsk, Pomorskie, Poland

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy